title: Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women.
abstract: Lopinavir (LPV) exposure is reduced during the third trimester of pregnancy. We report the pharmacokinetics of standard LPV-ritonavir dosing (400/100 mg twice daily) in the immediate and early postpartum period when initiated during labor. In 16 human immunodeficiency virus-infected Thai women, the median (range) LPV area under the concentration-time curve and maximum and minimum concentrations in plasma were 99.7 (66.1 to 180.5) microg x h/ml, 11.2 (8.0 to 17.5) microg/ml, and 4.6 (1.7 to 12.5) microg/ml, respectively, at 41 (12 to 74) h after delivery. All of the women attained adequate LPV levels through 30 days postpartum. No serious adverse events were reported.
authors.affiliation: Harvard School of Public Health, Boston, Massachusetts, USA. tim@phpt.org
authors.forename: Tim R
authors.initials: TR
authors.lastname: Cressey
authors.forename: Russell
authors.initials: R
authors.lastname: Van Dyke
authors.forename: Gonzague
authors.initials: G
authors.lastname: Jourdain
authors.forename: Thanyawee
authors.initials: T
authors.lastname: Puthanakit
authors.forename: Anuvat
authors.initials: A
authors.lastname: Roongpisuthipong
authors.forename: Jullapong
authors.initials: J
authors.lastname: Achalapong
authors.forename: Prapap
authors.initials: P
authors.lastname: Yuthavisuthi
authors.forename: Sinart
authors.initials: S
authors.lastname: Prommas
authors.forename: Nantasak
authors.initials: N
authors.lastname: Chotivanich
authors.forename: Robert
authors.initials: R
authors.lastname: Maupin
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Smith
authors.forename: David E
authors.initials: DE
authors.lastname: Shapiro
authors.forename: Mark
authors.initials: M
authors.lastname: Mirochnick
mesh_terms: D000293:Adolescent; D000328:Adult; D019540:Area Under Curve; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D061466:Lopinavir; D049590:Postpartum Period; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy* / Q000821:virology; D011263:Pregnancy Trimester, Third; D011744:Pyrimidinones / Q000008:administration & dosage / Q000493:pharmacokinetics* / Q000627:therapeutic use; D019438:Ritonavir / Q000493:pharmacokinetics; D013785:Thailand; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir